Welcome to our dedicated page for Matinas Biopharm SEC filings (Ticker: MTNB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Matinas BioPharma Holdings, Inc. filings document a clinical-stage biopharmaceutical issuer built around lipid nanocrystal delivery technology and MAT2203, its oral amphotericin B antifungal candidate. Regulatory disclosures include material-event reports, proxy matters, governance changes, capital-structure actions, and public-company compliance items.
Recent MTNB filings cover NYSE American continued-listing notices, board and officer changes, executive compensation arrangements, warrant exchanges, authorized-share amendments, stockholder meeting results, and equity incentive plan approvals. These records also disclose the company’s common-stock structure, voting matters, risk-related listing issues, and formal reporting obligations as a public biotechnology company.
Matinas BioPharma Holdings, Inc. reported a Q1 2026 net loss of $1.9M, similar to the prior year, with cash and cash equivalents of $2.4M and total assets of $5.9M. Stockholders’ equity fell to $3.0M, down from $6.3M a year earlier.
The company, a clinical-stage biopharma built around its lipid nanocrystal (LNC) delivery platform and lead asset MAT2203, cut research and development spending to zero in the quarter while general and administrative costs stayed around $1.9M. Management discloses substantial doubt about its ability to continue as a going concern.
Matinas is seeking to monetize MAT2203 through a license, sale or partnership and may use its At-The-Market Sales Agreement with BTIG, but capacity is capped by Form S-3 public float limits. The NYSE American has notified the company that it is below stockholders’ equity listing standards, and Matinas has submitted a compliance plan.
Matinas BioPharma Holdings, Inc. reported that it received a notice from NYSE American on April 2, 2026 stating it is not in compliance with the exchange’s continued listing standards because of low stockholders’ equity and multi-year losses.
As of December 31, 2025, stockholders’ equity was $4.83 million and the company reported losses in each of the most recent five fiscal years, below the $6.0 million equity requirement for issuers with five years of losses. Matinas has until May 2, 2026 to submit a plan and may have up to an 18‑month cure period if the plan is accepted. The company’s shares remain listed for now, but delisting proceedings could begin if NYSE American does not accept the plan or if compliance is not regained. The company also highlighted that its auditor’s report on the 2025 financial statements includes an explanatory paragraph raising substantial doubt about its ability to continue as a going concern.
Matinas BioPharma Holdings, Inc. files its annual report detailing a pivot from internal R&D toward partnering or monetizing its lead antifungal candidate MAT2203, built on its lipid nanocrystal platform. A terminated licensing negotiation in October 2024 led to an 80% workforce reduction, a pause of further clinical development and evaluation of strategic alternatives, including a potential asset sale or Company winddown.
To extend its cash runway, Matinas completed an April 2024 equity offering of 666,667 common shares and warrants for about $10 million, and a February–April 2025 preferred stock and warrant financing for $3.3 million. The company executed a 1‑for‑50 reverse stock split and later increased authorized common shares back to 500,000,000, enabling significant potential future issuance, including up to 16,894,212 shares tied to the preferred stock and 2025 warrants.
MAT2203 has FDA Fast Track, Qualified Infectious Disease Product and Orphan Drug designations, and Phase 2 data in cryptococcal meningitis show strong early fungicidal activity, high survival and markedly lower kidney toxicity than IV amphotericin B. However, progression to the FDA‑aligned Phase 3 ORALTO trial in invasive aspergillosis depends on securing a partner or additional capital, and there is no assurance a transaction will occur.
Matinas BioPharma Holdings, Inc. reported a leadership change in its finance function. Following the previously announced resignation of Chief Financial Officer Keith Kucinski effective January 17, 2026, the board appointed Jerome D. Jabbour, the company’s Chairman, President and Chief Executive Officer, as interim Chief Financial Officer effective January 22, 2026.
Jabbour, 51, is a co‑founder of the company and has held senior roles since 2013, including Chief Executive Officer since March 2018 and Chairman of the Board since March 2025. He will also serve as the company’s principal financial officer and principal accounting officer until a successor is appointed or he resigns or is removed. His existing compensation arrangements remain unchanged, and the company states there are no special appointment arrangements, family relationships, or related‑party transactions connected to this role.
Matinas BioPharma Holdings updated the employment agreement of its Chief Executive Officer, Jerome D. Jabbour, through a third amendment. The change extends the deadline for a qualifying Change in Control that would trigger his retention bonus from March 31, 2026 to June 30, 2026. The retention bonus remains the greater of his target annual bonus for the year of the Change in Control or $299,000.
The amendment also splits the retention bonus into two stages: two-thirds payable when Matinas signs a definitive agreement that would result in a Change in Control, and one-third payable immediately before closing, provided he has not resigned without Good Reason or been terminated for Cause. If he resigns for Good Reason or is terminated other than for Cause, the retention bonus becomes payable within ten days and no later than immediately before a Change in Control. Jabbour is guaranteed an annual bonus for 2025 of at least his target bonus, payable by February 1, 2026, and the definitions of Change in Control, Cause, and Good Reason are updated, including adding transactions that materially change the company’s primary business.
Matinas BioPharma Holdings, Inc. reported a planned leadership change. On November 18, 2025, Chief Financial Officer Keith Kucinski informed the company that he intends to resign from his role, effective January 17, 2026, to pursue other opportunities. The company stated that his decision is not due to any disagreement regarding its operations, policies, or practices, indicating an orderly transition rather than a dispute-driven departure.
Matinas BioPharma (MTNB): ownership update — Highbridge Capital Management, LLC filed Amendment No. 2 to Schedule 13G reporting 0% beneficial ownership of Matinas BioPharma common stock. The filing shows 0 shares beneficially owned with 0 sole or shared voting and dispositive power.
The date of event triggering the filing is 09/30/2025. Highbridge certifies the securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Matinas BioPharma Holdings (MTNB) reported Q3 2025 results. The company posted a Q3 net loss of $1.532 million and a nine‑month net loss of $8.433 million as it cut operating costs. Cash and cash equivalents were $5.435 million, with $0.250 million in restricted cash. Management states that cash on hand is not sufficient to fund planned operations beyond the next twelve months, and substantial doubt exists about the company’s ability to continue as a going concern.
Operating expenses fell sharply as R&D dropped to $0 in Q3 (from $2.239 million a year ago) and G&A was $1.577 million (from $2.142 million). A $3.161 million loss from the change in fair value of warrant liability was recognized before the warrants were amended and reclassified to equity. The company raised $3.3 million gross via a private placement of Series C Convertible Preferred Stock and accompanying warrants. Authorized common shares were increased to 500,000,000. Common shares outstanding were 5,901,091 as of September 30, 2025; 6,406,191 were outstanding as of November 6, 2025.
Disclosure controls and procedures were not effective due to an unresolved material weakness, with a remediation plan underway.
Amendment No. 2 to Schedule 13D for Matinas BioPharma Holdings, Inc. (MTNB) reports that Hezbay Holdings LLC and its sole member, Ari Kluger, beneficially own 253,841 common shares, representing 4.99% of 5,086,985 shares outstanding as of August 12, 2025. The Amendment states the Reporting Person withdrew from the previously disclosed Joint Filing Agreement and notes the holdings are subject to a contractual 4.99% ownership restriction. Because of that blocker, the Reporting Person indicates it is currently no longer required to file reports under Rule 13d. The Amendment incorporates this change into Item 6 and files no new exhibits.
Matinas BioPharma Holdings, Inc. (MTNB) Schedule 13G shows David E. Lazar reported beneficial ownership of 545,000 shares, equal to 9.81% of the company’s common stock based on 5,553,651 shares outstanding. The filing states those shares were beneficially owned as of the close of business on August 15, 2025. The cover data indicates 0 sole voting and dispositive power and 545,000 shares held with shared voting and dispositive power. The Reporting Person is identified as a registered investment adviser type (IA) and lists principal business address in Panama City, Panama. The filing includes a certification that the holdings were not acquired to influence control of the issuer.